InvestorsHub Logo
Followers 276
Posts 32704
Boards Moderated 0
Alias Born 11/14/2013

Re: GermanCol post# 525127

Wednesday, 10/26/2022 4:41:02 PM

Wednesday, October 26, 2022 4:41:02 PM

Post# of 701734
I completely disagree that the 35 patient group encompassed any DCVax-l recipients.

Instead, JTM 2018

Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L.



Note: 331 - 35 = 296

296/331= 89.4%

Or “nearly 90%”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News